<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">r-n-j</journal-id><journal-title-group><journal-title xml:lang="ru">Российский неврологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian neurological journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2658-7947</issn><issn pub-type="epub">2686-7192</issn><publisher><publisher-name>МИА</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.30629/2658-7947-2025-30-2-27-31</article-id><article-id custom-type="elpub" pub-id-type="custom">r-n-j-683</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ИССЛЕДОВАНИЯ И КЛИНИЧЕСКИЕ НАБЛЮДЕНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL RESEARCHES AND CASE REPORTS</subject></subj-group></article-categories><title-group><article-title>Легкая цепь нейрофиламента в крови и особенности течения рассеянного склероза у пациентов с черепно-мозговой травмой в анамнезе</article-title><trans-title-group xml:lang="en"><trans-title>Neurofilament light chain in blood and features of the multiple sclerosis course in patients with a history of traumatic brain injury</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7507-3963</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Афанасьева</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Afanasyeva</surname><given-names>A. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Барнаул</p></bio><bio xml:lang="en"><p>Barnaul</p></bio><email xlink:type="simple">lac-alisa@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4500-4913</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ельчанинова</surname><given-names>Е. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Elchaninova</surname><given-names>E. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Барнаул</p></bio><bio xml:lang="en"><p>Barnaul</p></bio><email xlink:type="simple">ekaterina_chukina@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7947-4529</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Смагина</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Smagina</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Барнаул</p></bio><bio xml:lang="en"><p>Barnaul</p></bio><email xlink:type="simple">siv7000@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2730-615X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ельчанинова</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Elchaninova</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Барнаул</p></bio><bio xml:lang="en"><p>Barnaul</p></bio><email xlink:type="simple">saelch@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО «Алтайский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Altai State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>10</day><month>06</month><year>2025</year></pub-date><volume>30</volume><issue>2</issue><fpage>27</fpage><lpage>31</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Афанасьева А.И., Ельчанинова Е.Ю., Смагина И.В., Ельчанинова С.А., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Афанасьева А.И., Ельчанинова Е.Ю., Смагина И.В., Ельчанинова С.А.</copyright-holder><copyright-holder xml:lang="en">Afanasyeva A.I., Elchaninova E.Y., Smagina I.V., Elchaninova S.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.r-n-j.com/jour/article/view/683">https://www.r-n-j.com/jour/article/view/683</self-uri><abstract><p>Рассеянный склероз (РС) — хроническое заболевание центральной нервной системы с рецидивирующими обострениями, приводящее к необратимой инвалидизации, в основе развития которой лежит повреждение аксонов и демиелинизация. Предполагается, что одним из биомаркеров повреждения аксонов может быть пептидный компонент цитоскелета нейронов — легкая цепь нейрофиламента (ЛЦНФ) (neurofilament light chain (NFL)). Черепно-мозговая травма (ЧМТ), полученная до дебюта РС, ассоциируется с повышенной скоростью прогрессирования (СП) неврологических расстройств, что может быть связано с усиленным астроглиозом как отдаленным последствием ЧМТ. Цель исследования: оценить связь уровня ЛЦНФ в крови со скоростью прогрессирования и частотой обострений РС при наличии/отсутствии ЧМТ до дебюта РС.</p><sec><title>Материал и методы</title><p>Материал и методы. Европеоиды, родившиеся и проживающие в Алтайском крае России, с ремиттирующим РС в состоянии ремиссии приняли участие в одномоментном наблюдательном рандомизированном исследовании: 43 пациента без ЧМТ в анамнезе и 43 пациента с ЧМТ до дебюта РС (длительность РС 7,6 ± 6,6 и 5,9 ± 4,6 лет, соответственно, p = 0,113). ЧМТ была получена за 14,8 ± 7,8 лет до дебюта РС и документирована у 76% пациентов как сотрясение головного мозга.</p></sec><sec><title>Результаты</title><p>Результаты. Группы пациентов не различались по частоте обострений РС, тогда как СП была выше в группе с ЧМТ в анамнезе (p = 0,013). Не выявлено межгрупповых различий по уровню ЛЦНФ (p = 0.613), а также значимых корреляций уровня ЛЦНФ со СП и частотой обострений РС (p = 0.499 и p = 0.776 в группах с/без ЧМТ, соответственно). Уровни ЛЦНФ в подгруппах пациентов с разными клиническими формами ЧМТ не различались (H = 5,07; p = 0,679).</p></sec><sec><title>Заключение</title><p>Заключение. Результаты исследования указывают на малую вероятность связи уровня ЛЦНФ в крови больных РС в период ремиссии как с возможными отдаленными последствиями ЧМТ, полученной до дебюта РС, так и с течением РС.</p></sec></abstract><trans-abstract xml:lang="en"><p>Multiple sclerosis (MS) is a chronic disease of the central nervous system with recurrent exacerbations, leading to irreversible disability, the development of which is based on axonal damage and demyelination. It is assumed that one of the candidate biomarkers of axonal damage may be a peptide component of the neuronal cytoskeleton — neurofilament light chain (NFL). Traumatic brain injury (TBI) before the onset of MS is associated with an increased rate of progression of neurological which may be due to increased astrogliosis as a late consequence of TBI. Objective: to evaluate the relationship between the level of NFL in the blood and the RP and exacerbation frequency MS in the presence/absence of TBI before the onset of MS.</p><sec><title>Material and methods</title><p>Material and methods. Caucasians born and living in the Altai region of Russia with relapsing-remitting MS in remission took part in a cross-sectional observational randomized study: 43 patients without a history of TBI and 43 patients with TBI before the onset of MS (MS duration 7.6 ± 6.6 and 5.9 ± 4.6 years, respectively, p = 0,113). Intracranial injury occurred 14.8 ± 7.8 years before the onset of MS and was documented as a concussion in 76% of patients.</p></sec><sec><title>Results</title><p>Results. The patient groups did not differ in the frequency of MS exacerbations, while RP was higher in the group with a history of TBI (p = 0.013). There were no intergroup differences in NFL levels (p = 0.613), as well as no correlations between NFL levels and RP (p = 0.499 and p = 0.776 groups with/without TBI, respectively) and the exacerbation frequency. No differences were found between subgroups of patients with different clinical forms of TBI in RP and NFL levels (H = 5,07; p = 0,679).</p></sec><sec><title>Conclusion</title><p>Conclusion. The results of the study indicate a low probability of a connection between the level of NFL in the blood of patients with MS during the period of remission, both with the possible long-term consequences of a TBI received before the onset of MS, and with the course of MS.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>рассеянный склероз</kwd><kwd>черепно-мозговая травма</kwd><kwd>биомаркер</kwd><kwd>легкая цепь нейрофиламента</kwd></kwd-group><kwd-group xml:lang="en"><kwd>multiple sclerosis</kwd><kwd>traumatic brain injury</kwd><kwd>biomarker</kwd><kwd>neurofilament light chain</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Шмидт Т.Е., Яхно Н.Н. Рассеянный склероз: от патогенеза через клинику к лечению /Т.Е. Шмидт, Н.Н. Яхно. Москва, МЕДпресс-информ, 2021. 368 с.: ил.</mixed-citation><mixed-citation xml:lang="en">Schmidt T.E., Yakhno N.N. Multiple sclerosis: from pathogenesis to clinical presentation to treatment / T.E. Schmidt, N.N. Yakhno. Moscow, MEDpress-inform, 2021. 368 p.: ill. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Pachner A.R. The Neuroimmunology of Multiple Sclerosis: Fictions and Facts. Front Neurology. 2022;7(12):796378. doi: 10.3389/fneur.2021.796378</mixed-citation><mixed-citation xml:lang="en">Pachner A.R. The Neuroimmunology of Multiple Sclerosis: Fictions and Facts. Front Neurology. 2022;7(12):796378. doi: 10.3389/fneur.2021.796378</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Husseini L., Geladaris A., Weber M.S. Toward identifying key mechanisms of progression in multiple sclerosis. Trends Neuroscience. 2024;47(1):58–70. doi: 10.1016/j.tins.2023.11.005 Epub 2023 Dec 14. PMID: 38102058.</mixed-citation><mixed-citation xml:lang="en">Husseini L., Geladaris A., Weber M.S. Toward identifying key mechanisms of progression in multiple sclerosis. Trends Neuroscience. 2024;47(1):58–70. doi: 10.1016/j.tins.2023.11.005 Epub 2023 Dec 14. PMID: 38102058.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Bittner S., Oh. J., Havrdová E.K., Tintoré M., Zipp F. The potential of serum neurofilament as biomarker for multiple sclerosis. Brain. 2021;29;144(10):2954–2963. doi: 10.1093/brain/awab241 PMID: 34180982; PMCID: PMC8634125.</mixed-citation><mixed-citation xml:lang="en">Bittner S., Oh. J., Havrdová E.K., Tintoré M., Zipp F. The potential of serum neurofilament as biomarker for multiple sclerosis. Brain. 2021;29;144(10):2954–2963. doi: 10.1093/brain/awab241 PMID: 34180982; PMCID: PMC8634125.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Cai L., Huang J. Neurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis study. Neuropsychiatric Disease and Treatment. 2018;14:2241–2254. doi: 10.2147/NDT.S173280</mixed-citation><mixed-citation xml:lang="en">Cai L., Huang J. Neurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis study. Neuropsychiatric Disease and Treatment. 2018;14:2241–2254. doi: 10.2147/NDT.S173280</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Shlosberg D., Benifla M., Kaufer D., Friedman A. Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nature Reviews Neurology. 2010;6(7):393–403. doi: 10.1038/nrneurol.2010.74</mixed-citation><mixed-citation xml:lang="en">Shlosberg D., Benifla M., Kaufer D., Friedman A. Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nature Reviews Neurology. 2010;6(7):393–403. doi: 10.1038/nrneurol.2010.74</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Sivandzade F., Alqahtani F., Cucullo L. Traumatic Brain Injury and Blood-Brain Barrier (BBB): Underlying Pathophysiological Mechanisms and the Influence of Cigarette Smoking as a Premorbid Condition. International Journal of Molecular Sciences. 2020;21(8):2721. doi: 10.3390/ijms21082721</mixed-citation><mixed-citation xml:lang="en">Sivandzade F., Alqahtani F., Cucullo L. Traumatic Brain Injury and Blood-Brain Barrier (BBB): Underlying Pathophysiological Mechanisms and the Influence of Cigarette Smoking as a Premorbid Condition. International Journal of Molecular Sciences. 2020;21(8):2721. doi: 10.3390/ijms21082721</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ельчанинова Е.Ю., Афанасьева А.И., Смагина И.В., Ельчанинова С.А. Черепно-мозговая травма до дебюта рассеянного склероза: связь с прогрессированием неврологических расстройств и патобиохимическими показателями цереброспинальной жидкости. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023;123(7/2):72–76. doi: 10.17116/jnevro202312307272</mixed-citation><mixed-citation xml:lang="en">Elchaninova E.Yu., Afanas’eva A.I., Smagina I.V., Elchaninova S.A. Traumatic brain injury before the multiple sclerosis onset: a relationship with the progression of neurological disorders and pathobiochemical markers of the cerebrospinal fluid. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(7/2):72–76. (In Russ.) doi: 10.17116/jnevro202312307272</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ельчанинова Е.Ю., Афанасьева А.И., Смагина И.В., Ельчанинова С.А. Глиальный фибриллярный кислый белок: есть ли связь с течением рассеянного склероза и черепно-мозговой травмой до дебюта рассеянного склероза? Журнал неврологии и психиатрии им. С.С. Корсакова. 2024;124(10):80–84.</mixed-citation><mixed-citation xml:lang="en">Elchaninova E.Yu., Afanas’eva A.I., Smagina I.V., Elchaninova S.A. Glial fibrillary acidic protein: is there a relationship with the course of multiple sclerosis and traumatic brain injury before the onset of multiple sclerosis? S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(10):80–84. (In Russ.) doi: 10.17116/jnevro202412410180</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., Fujihara K., Havrdova E., Hutchinson M., Kappos L., Lublin F.D., Montalban X., O’Connor P., Sandberg-Wollheim M., Thompson A.J., Waubant E., Weinshenker B., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Annals of neurology. 2011;69(2):292–302. doi: 10.1002/ana.22366</mixed-citation><mixed-citation xml:lang="en">Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., Fujihara K., Havrdova E., Hutchinson M., Kappos L., Lublin F.D., Montalban X., O’Connor P., Sandberg-Wollheim M., Thompson A.J., Waubant E., Weinshenker B., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Annals of neurology. 2011;69(2):292–302. doi: 10.1002/ana.22366</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Thompson A.J., Banwell B.L., Barkhof F., Carroll W.M., Coetzee T., Comi G., Correale J., Fazekas F., Filippi M., Freedman M.S., Fujihara K., Galetta S.L., Hartung H.P., Kappos L., Lublin F.D., Marrie R.A., Miller A.E., Miller D.H., Montalban X., Mowry E.M., Sorensen P.S., Tintoré M., Traboulsee A.L., Trojano M., Uitdehaag B.M.J., Vukusic S., Waubant E., Weinshenker B.G., Reingold S.C., Cohen J.A. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology. 2017. doi: 1016/S1474-4422(17)30470-2</mixed-citation><mixed-citation xml:lang="en">Thompson A.J., Banwell B.L., Barkhof F., Carroll W.M., Coetzee T., Comi G., Correale J., Fazekas F., Filippi M., Freedman M.S., Fujihara K., Galetta S.L., Hartung H.P., Kappos L., Lublin F.D., Marrie R.A., Miller A.E., Miller D.H., Montalban X., Mowry E.M., Sorensen P.S., Tintoré M., Traboulsee A.L., Trojano M., Uitdehaag B.M.J., Vukusic S., Waubant E., Weinshenker B.G., Reingold S.C., Cohen J.A. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology. 2017. doi: 1016/S1474-4422(17)30470-2</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kurtzke, J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–1452. doi: 10.1212/WNL.33.11.1444</mixed-citation><mixed-citation xml:lang="en">Kurtzke, J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–1452. doi: 10.1212/WNL.33.11.1444</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Portaccio E., Magyari M., Havrdova E.K., Ruet A., Brochet B., Scalfari A., Di Filippo M., Tur C., Montalban X., Amato M.P. Multiple sclerosis: emerging epidemiological trends and redefining the clinical course. The Lancet Regional Health Europe. 2024 Aug 22;44:100977. https://doi:10.1016/j.lanepe.2024.100977 PMID: 39444703; PMCID: PMC11496978.</mixed-citation><mixed-citation xml:lang="en">Portaccio E., Magyari M., Havrdova E.K., Ruet A., Brochet B., Scalfari A., Di Filippo M., Tur C., Montalban X., Amato M.P. Multiple sclerosis: emerging epidemiological trends and redefining the clinical course. The Lancet Regional Health Europe. 2024 Aug 22;44:100977. https://doi:10.1016/j.lanepe.2024.100977 PMID: 39444703; PMCID: PMC11496978.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Chertcoff A., Schneider R., Azevedo C.J., Sicotte N., Oh. J. Recent Advances in Diagnostic, Prognostic, and Disease-Monitoring Biomarkers in Multiple Sclerosis. Neurologic Clinics. 2024;42(1):15– 38. doi: 10.1016/j.ncl.2023.06.008 Epub 2023 Aug 5. PMID: 37980112.</mixed-citation><mixed-citation xml:lang="en">Chertcoff A., Schneider R., Azevedo C.J., Sicotte N., Oh. J. Recent Advances in Diagnostic, Prognostic, and Disease-Monitoring Biomarkers in Multiple Sclerosis. Neurologic Clinics. 2024;42(1):15– 38. doi: 10.1016/j.ncl.2023.06.008 Epub 2023 Aug 5. PMID: 37980112.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Williams T., Zetterberg H., Chataway J. Neurofilaments in progressive multiple sclerosis: a systematic review. Journal of Neurology. 2021;268(9):3212–3222. doi: 10.1007/s00415-020-09917-x Epub 2020 May 23. PMID: 32447549; PMCID: PMC8357650</mixed-citation><mixed-citation xml:lang="en">Williams T., Zetterberg H., Chataway J. Neurofilaments in progressive multiple sclerosis: a systematic review. Journal of Neurology. 2021;268(9):3212–3222. doi: 10.1007/s00415-020-09917-x Epub 2020 May 23. PMID: 32447549; PMCID: PMC8357650</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
